April 7, 2022
IGM Announces Closing of $230.0 Million Public Offering
MOUNTAIN VIEW, Calif., April 06, 2022 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the closing on April…
Pharmaceuticals, Biotechnology and Life Sciences
MOUNTAIN VIEW, Calif., April 06, 2022 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the closing on April…
PHILADELPHIA, April 06, 2022 (GLOBE NEWSWIRE) — Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell…
SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present…
Revenue Sharing Arrangement with University of Oxford Could Deliver Further Payments to Vaccitech Arising from Milestones and RoyaltiesOXFORD, United Kingdom,…
ZUG, Switzerland, April 06, 2022 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to…
SAN DIEGO and GAINESVILLE, Ga., April 06, 2022 (GLOBE NEWSWIRE) — Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL), a contract…
ERYTECH Announces Publication of Positive Results from Eryaspase Phase 2 Trial in Hypersensitive ALL in the British Journal of Haematology…
CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and…
Company anticipates completing IND amendment process by mid-2022 to enable dosing of the first patient in the planned Phase 2…
Low rate of COVID-19 infection observed in vaccinated, durably chimeric patients off immunosuppression No evidence of acute kidney injury or impaired…